Have a feature idea you'd love to see implemented?
Let us know!
RENB Renovaro Biosciences Inc
Price (delayed)
$0.9065
Market cap
$143.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.85
Enterprise value
$147.48M
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and
Highlights
The debt has declined by 17% year-on-year
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
Renovaro Biosciences's quick ratio has shrunk by 63% YoY but it has surged by 50% QoQ
Renovaro Biosciences's net income has plunged by 181% YoY and by 43% from the previous quarter
The company's EPS fell by 20% YoY
Key stats
What are the main financial stats of RENB
Market
Valuations
Earnings
Shares outstanding
158.72M
Market cap
$143.88M
Enterprise value
$147.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$115.69M
EBIT
-$114.58M
EBITDA
-$114.45M
Free cash flow
-$10.28M
Per share
Balance sheet
Liquidity
EPS
-$0.85
EPS diluted
-$0.85
Free cash flow per share
-$0.07
Book value per share
$0.66
Revenue per share
$0
TBVPS
$0.02
Total assets
$121.83M
Total liabilities
$23.75M
Debt
$3.82M
Equity
$98.09M
Working capital
-$21.09M
Debt to equity
0.04
Current ratio
0.08
Quick ratio
0.06
Net debt/EBITDA
-0.03
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-88.8%
Return on equity
-113.4%
Return on invested capital
N/A
Return on capital employed
-116%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RENB stock price
How has the Renovaro Biosciences stock price performed over time
Intraday
-11.99%
1 week
-41.33%
1 month
75.37%
1 year
-72.7%
YTD
-71.4%
QTD
87.56%
Financial performance
How have Renovaro Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$126.09M
Net income
-$115.69M
Gross margin
N/A
Net margin
N/A
Renovaro Biosciences's net income has plunged by 181% YoY and by 43% from the previous quarter
RENB's operating income has shrunk by 54% QoQ
Growth
What is Renovaro Biosciences's growth rate over time
Valuation
What is Renovaro Biosciences stock price valuation
P/E
N/A
P/B
1.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 20% YoY
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
The stock's P/B is 48% below its last 4 quarters average of 2.6 and 24% below its 5-year quarterly average of 1.8
Efficiency
How efficient is Renovaro Biosciences business performance
RENB's ROE has dropped by 56% year-on-year and by 25% since the previous quarter
The ROA has contracted by 48% YoY and by 26% from the previous quarter
Dividends
What is RENB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RENB.
Financial health
How did Renovaro Biosciences financials performed over time
The company's total liabilities has surged by 120% YoY but it fell by 24% QoQ
RENB's total assets has soared by 112% YoY but it is down by 25% QoQ
The debt is 96% smaller than the equity
The equity has surged by 110% year-on-year but it has declined by 26% since the previous quarter
The debt to equity has dropped by 60% year-on-year but it has increased by 33% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.